Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC]: Side Effects & Safety Data for 5 Drugs
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] includes 5 drugs with a combined 53,244 adverse event reports in the FDA FAERS database. Compare their safety profiles, side effects, and outcomes below.
5
Drugs in Class
53,244
Combined Reports
All Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Drugs Ranked by Reports
| Drug | Brand Name | Reports | Deaths | Hosp. | Death Rate |
|---|---|---|---|---|---|
| TENOFOVIR DISOPROXIL | Tenofovir Disoproxil Fumarate | 26,978 | 1,235 | 3,617 | 4.6% |
| LAMIVUDINE | Lamivudine and Zidovudine | 16,685 | 1,838 | 3,442 | 11.0% |
| ENTECAVIR | Entecavir | 4,487 | 726 | 1,133 | 16.2% |
| TENOFOVIR ALAFENAMIDE | VEMLIDY | 2,990 | 311 | 713 | 10.4% |
| ADEFOVIR DIPIVOXIL | Adefovir dipivoxil | 2,104 | 89 | 709 | 4.2% |
Common Side Effects in Hepatitis B Virus Nucleoside Analog Reverse Transcriptase Inhibitor [EPC] Drugs
| Side Effect | Reports | Deaths |
|---|---|---|
| Bone density decreased | 10,727 | 159 |
| Renal injury | 9,371 | 168 |
| Skeletal injury | 8,320 | 172 |
| Chronic kidney disease | 7,417 | 220 |
| Osteonecrosis | 7,293 | 107 |
| Bone loss | 7,052 | 107 |
| Multiple fractures | 6,883 | 110 |
| Renal failure | 6,748 | 347 |
| Osteoporosis | 5,746 | 80 |
| Tooth loss | 4,483 | 57 |